<DOC>
	<DOCNO>NCT00986765</DOCNO>
	<brief_summary>Preeclampsia ( PE ) complicate 2-8 % pregnancy . It associate increase risk adverse maternal ( death , eclampsia , abruptio placenta , HELLP syndrome ) perinatal ( perinatal death , growth restriction , prematurity ) outcomes . The definite treatment PE remain pregnancy termination . Therefore , prevention PE remain important challenge . Low dose aspirin may use prevention PE , particularly woman severe preeclampsia 34 week . Its efficiency , however , weak . Recently , suggest low molecular weight heparin might useful prevention PE . The aim study analyze usefulness enoxaparin 4000 UI/day prevention composite maternal perinatal morbidity ( occurrence one follow event : maternal death , PE , fetal growth retardation , abruptio placenta , perinatal death ) woman previously severe preeclampsia le 34 week ' gestation . To answer question , investigator propose conduct multicenter prospective randomize trial compare two group parallel : group woman association enoxaparin 4000 U/day aspirin 100 mg/day another group woman would aspirin 100 mg/day . The number patient need 255 ( amendment n°2-approved 06/12/2011 ) .</brief_summary>
	<brief_title>Prevention Maternal Perinatal Complications Enoxaparin Women With Previous Severe Preeclampsia</brief_title>
	<detailed_description>1 . Purpose study : To determine whether low molecular weight heparin ( LMWH ) enoxaparin decrease rate maternal perinatal composite morbidity woman previously severe preeclampsia occur less 34 week ' gestation . 2 . Patients method : Multicenter , prospective , randomized trial compare 2 group patient : - First group treat aspirin 100 mg/day 35 week ' gestation enoxaparin subcutaneous 4000 UI/day delivery . - Second group treat aspirin 100 mg/day alone 35 week ' gestation . At first prenatal visit 7-13 week , inclusion exclusion criterion search . Randomization perform internet software . It perform center . After randomization first prenatal visit patient allocate aspirin-enoxaparin aspirin alone mention . Enoxaparin stop day delivery occurrence complication necessitate delivery . Pregnancy management perform recommended standard care . Each month , blood sample draw platelet count analysis angiogenic factor ( sFlt1 , sEng , free PlGF VEGF ) . In addition , blood sample drawn first prenatal visit thrombophilia work-up ( Prot C , Factor V Leiden , Prothrombin gene polymorphism ) . Only result platelet count give local investigator study . All analysis perform end study Pr Gris NIMES , blind clinical result . 3 . Statistical analysis : Women previous severe preeclampsia le 34 week ' gestation 40 % risk occurrence composite morbidity ( primary outcome define ) next pregnancy . A 33 % decrease composite morbidity define woman treat LMWH enoxaparin consider efficient . With alpha risk .05 beta risk .20 , number patient need 255 ( amendment n°2-approved 06/12/2011 ) . This trial analyze `` Intention treat study '' . No interim analysis primary outcome perform . Results stratify center . Primary outcome ( categorical variable ) analyze chi-square test . Secondary outcome analyze chi-square test categorical variable ANOVA continuous variable . Statistical significance consider p value &lt; .05 . Statistical analysis perform STATA software ( StataCorp , 2003 , TX ) . 4 . Registry non-included patient : Each patient non-eligible trial note registry well reason exclusion . 5 . Independent committee analysis adverse outcome : An independent committee analyze adverse maternal perinatal outcomes statistical analysis end study . This analysis blind treatment allocated patient . 6 . Definitions : - Preeclampsia : Preeclampsia define association gestational hypertension ( 20 week ' gestation , systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg , persistent least 4 hour apart , persistent diastolic blood pressure &gt; 110 mmHg ) proteinuria ( 24 hour proteinuria &gt; 300 mg , least 1+ persistent least 4 hour apart ) . - Fetal growth restriction : Fetal growth restriction define birthweight &lt; 10th percentile . - Abruptio placenta : Abruptio placenta define association bleed one follow criterion : - Abnormal fetal heart rate , - Abdominal pain , - Perinatal death : Perinatal death death occur fetal neonatal Period , 22 week ' gestation 28th day life . - Severe preeclampsia define , woman preeclampsia , presence one follow criterion : Maternal : - Severe hypertension ( systolic blood pressure &gt; 160 MmHg and/or diastolic blood pressure &gt; 110 mm Hg ) , - Persistent headache visual disturbance , - Persistent epigastric RUQ pain , - 24 hour proteinuria ≥ 5gr , - Oliguria &lt; 500 ml/24h , serum creatinine &gt; 120 µmol/L , - Eclampsia , - Pulmonary edema , - Abruption , - Platelet count &lt; 100,000/ µL , - lactate dehydrogenase ( LDH ) &gt; 600U/L , aspartate transaminase ( ASAT ) &gt; 2 normal . Fetal : - Severe fetal growth restriction ( &lt; 5ème percentile ) - Severe Oligohydramnios .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Acetylsalicylic acid lysinate</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Patient ≥ 18 year Patient previous severe preeclampsia occur less 34 week ' gestation Patient 7 13 week +6 day first prenatal visit Singleton pregnancy Affiliation social security Informed consent give receive information study . Patient law protection Inability sign write consent Inability follow protocol psychiatric disease History deep venous thromboembolism previous pregnancy Need low molecular weight heparin pregnancy Previous arterial thrombosis Patient cardiac valvular prosthesis necessitate anticoagulation pregnancy Renal failure ( creatinine clearance &lt; 30 ml/min , serum creatinine &gt; 180 µmol/L Previous hemorrhagic disease A disease might bleed ( gastric ulcer ) Antiphospholipid antibody syndrome Allergy Aspirin Allergy heparin Thrombocytopenia relate heparin use Thrombocytopenia &lt; 100,000 /µL first prenatal visit Antecedent osteoporosis Inability subcutaneous injection heparin Weight &gt; 100 kg Patient include another interventional trial Patient positive antiphospholipids antibody Patient positive HIV HCV HBS</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Fetal growth restriction</keyword>
	<keyword>Abruptio placenta</keyword>
	<keyword>Perinatal death</keyword>
</DOC>